Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Follow-Up Questions
Scienture Holdings Inc (SCNX)의 PER은 얼마입니까?
Scienture Holdings Inc의 PER은 1.8451입니다
SCNX 주식의 가격 성능은 어떻습니까?
SCNX의 현재 가격은 $0.792이며, 전 거래일에 decreased 3.2% 하였습니다.
Scienture Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
Scienture Holdings Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
